GlassScriptPhysician profile
Melissa Maybury
NPI 1710344981
$3,940.77
in general payments reported to CMS, 2019-2025
19 companies · $688 in 2025
The $688 reported for 2025 was more than what a typical Psychiatric/Mental Health (Nurse Practitioner) provider received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $241 · 2022: $208 · 2023: $549 · 2024: $2,255 · 2025: $688.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,498 · Travel and Lodging: $993.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,498.46 |
| Travel and Lodging | $993.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Convatec INC. | $1,447.48 | 2024 | |
| Janssen Pharmaceuticals, INC | $829.83 | 2021-2025 | Spravato, Invega Sustenna, Invega Trinza |
| Abbvie INC. | $413.53 | 2021-2025 | |
| Otsuka America Pharmaceutical, INC. | $253.15 | 2022-2024 | Abilify Maintena, Abilify Asimtufii, Rexulti |
| Axsome Therapeutics, INC. | $231.71 | 2025 | Auvelity |
| Vanda Pharmaceuticals INC. | $133.75 | 2021-2025 | Fanapt, Hetlioz |
| Indivior INC. | $118.83 | 2021-2024 | Perseris |
| Biogen, INC. | $114.44 | 2024 | |
| Biohaven Pharmaceuticals, INC. | $82.55 | 2021 | |
| Alkermes, INC. | $73.40 | 2022-2024 | Aristada, Lybalvi, Vivitrol |
| Neurocrine Biosciences, INC. | $57.07 | 2023-2024 | Ingrezza |
| Teva Pharmaceuticals USA, INC. | $39.57 | 2025 | Austedo Xr |
| Sunovion Pharmaceuticals INC. | $28.49 | 2021 | |
| Corium, LLC | $25.99 | 2023 | Azstarys |
| Pharmacyclics LLC, An Abbvie Company | $24.81 | 2023 | Epkinly |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lundbeck LLC | $18.67 | 2024 | Rexulti |
| E.R. Squibb & Sons, L.L.C. | $17.35 | 2025 | Cobenfy |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $16.66 | 2025 | Caplyta |
| Lilly USA, LLC | $13.49 | 2024 | Zepbound, Jardiance |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Melissa Maybury listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.